{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:23:27Z","timestamp":1790735007160,"version":"4.1.0"},"reference-count":206,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Herpes simplex virus types 1 and 2 HSV1 and 2, namely varicella-zoster VZV and cytomegalovirus CMV, are among the most common pathogens worldwide. They remain in the host body for life. The course of infection with these viruses is often asymptomatic or mild and self-limiting, but in immunocompromised patients, such as solid organ or bone marrow transplant recipients, the course can be very severe or even life-threatening. Unfortunately, in the latter group, the highest percentage of infections with strains resistant to routinely used drugs is observed. On the other hand, frequent recurrences of genital herpes can be a problem even in people with normal immunity. Genital herpes also increases the risk of acquiring sexually transmitted diseases, including HIV infection and, if present in pregnant women, poses a risk to the fetus and newborn. Even more frequently than herpes simplex, congenital infections can be caused by cytomegalovirus. We present the most important anti-herpesviral agents, the mechanisms of resistance to these drugs, and the associated mutations in the viral genome. Special emphasis was placed on newly introduced drugs such as maribavir and brincidofovir. We also briefly discuss the most promising substances in preclinical testing as well as immunotherapy options and vaccines currently in use and under investigation.<\/jats:p>","DOI":"10.3390\/ijms23073431","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T14:55:35Z","timestamp":1647960935000},"page":"3431","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs?"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9036-7452","authenticated-orcid":false,"given":"Anna","family":"Majewska","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology, Medical University of Warsaw, Cha\u0142ubi\u0144skiego 5, 02-004 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Mlynarczyk-Bonikowska","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Immunodermatology and Venereology, Medical University of Warsaw, Koszykowa 82a, 02-008 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"key":"ref_1","first-page":"26","article-title":"Emerging trends, challenges and prospects in antiviral therapeutics and drug development for infectious diseases","volume":"6","author":"Saxena","year":"2010","journal-title":"Electron. J. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Tortella, G., Rubilar, O., Fincheira, P., Pieretti, J.C., Duran, P., Louren\u00e7o, I.M., and Seabra, A.B. (2021). Bactericidal and virucidal activities of biogenic metal-based nanoparticles: Advances and perspectives. Antibiotics, 10.","DOI":"10.3390\/antibiotics10070783"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Begines, B., Ortiz, T., P\u00e9rez-Aranda, M., Mart\u00ednez, G., Merinero, M., Arg\u00fcelles-Arias, F., and Alcudia, A. (2020). Polymeric nanoparticles for drug delivery: Recent developments and future prospects. Nanomaterials, 10.","DOI":"10.3390\/nano10071403"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2018.05.005","article-title":"Innovation and trends in the development and approval of antiviral medicines: 1987\u20132017 and beyond","volume":"155","author":"Chaudhuri","year":"2018","journal-title":"Antiviral. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e00105-19","DOI":"10.1128\/CMR.00105-19","article-title":"Immunomodulatory strategies in herpes simplex virus encephalitis","volume":"33","author":"Piret","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_6","first-page":"637","article-title":"In vitro inhibition of HHV-1 replication by inosine pranobex and interferon-\u03b1","volume":"73","author":"Majewska","year":"2016","journal-title":"Acta Pol. Pharm."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/fcp.12609","article-title":"Antiviral therapies: Advances and perspectives","volume":"35","author":"BelebechaTerezo","year":"2021","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1097\/ICO.0000000000001982","article-title":"Use of topical steroids in conjunctivitis: A review of the evidence","volume":"38","author":"Holland","year":"2019","journal-title":"Cornea"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5604\/12321966.1152063","article-title":"Animal herpesviruses and their zoonotic potential for cross-species infection","volume":"22","year":"2015","journal-title":"Ann. Agric. Environ. Med."},{"key":"ref_10","unstructured":"(2022, January 31). International Committee on Taxonomy of Viruses (ICTV). Available online: https:\/\/talk.ictvonline.org\/taxonomy\/."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2174\/138161206776361147","article-title":"Understanding helicases as a means of virus control","volume":"12","author":"Frick","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Shiraki, K., Yasumoto, S., Toyama, N., and Fukuda, H. (2021). Amenamevir, a helicase-primase inhibitor, for the optimal treatment of herpes zoster. Viruses, 13.","DOI":"10.3390\/v13081547"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"210011","DOI":"10.1098\/rsob.210011","article-title":"The three-component helicase\/primase complex of herpes simplex virus-1","volume":"11","author":"Bermek","year":"2021","journal-title":"Open. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Van de Sand, L., Bormann, M., Schmitz, Y., Heilingloh, C.S., Witzke, O., and Krawczyk, A. (2021). Antiviral active compounds derived from natural sources against herpes simplex viruses. Viruses, 13.","DOI":"10.3390\/v13071386"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.2174\/13895575113136660088","article-title":"Antiviral medication in sexually transmitted diseases. Part, I.: HSV, HPV","volume":"13","author":"Majewska","year":"2013","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Arvin, A., Campadelli-Fiume, G., and Mocarski, E. (2007). Pathogenesis and disease. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, Cambridge University Press. Chapter 32.","DOI":"10.1017\/CBO9780511545313"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1615\/CritRevOncog.2020032961","article-title":"The role of oncogenic DNA viruses in penile cancer development","volume":"24","author":"Cavalcanti","year":"2019","journal-title":"Crit. Rev. Oncog."},{"key":"ref_18","first-page":"291","article-title":"Possibilities of prevention and treatment of human cytomegalovirus infections including new drugs and compounds with potential application","volume":"58","author":"Majewska","year":"2019","journal-title":"Adv. Microbiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev-virology-020420-014025","article-title":"Herpesvirus epigenetic reprogramming and oncogenesis","volume":"7","author":"Pei","year":"2020","journal-title":"Annu. Rev. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10637-016-0409-9","article-title":"A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone","volume":"35","author":"Cleary","year":"2017","journal-title":"Investig. New Drugs."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1073\/pnas.74.12.5716","article-title":"Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine","volume":"74","author":"Elion","year":"1977","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"Li","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0190-9622(88)70022-5","article-title":"History, pharmacokinetics, and pharmacology of acyclovir","volume":"18","author":"King","year":"1988","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1055\/s-2006-931570","article-title":"N-acetylphenylisoserinates of Lactarius sesquiterpenoid alcohols-cytotoxic, antiviral, antiproliferative and immunotropic activities in vitro","volume":"72","author":"Krawczyk","year":"2006","journal-title":"Planta Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bioorg.2016.03.002","article-title":"Novel analogs of alloferon: Synthesis, conformational studies, pro-apoptotic and antiviral activity","volume":"66","author":"Kuczer","year":"2016","journal-title":"Bioorg. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-981-10-7230-7_6","article-title":"Antiviral Drugs Against Alphaherpesvirus","volume":"Volume 1045","author":"Kawaguchi","year":"2018","journal-title":"Human Herpesviruses. Advances in Experimental Medicine and Biology"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Li, G., Yue, T., Zhang, P., Gu, W., Gao, L.-W., and Tan, L. (2021). Drug discovery of nucleos(t)ide antiviral agents: Dedicated to prof. dr. Erik De Clercq on occasion of his 80th birthday. Molecules, 26.","DOI":"10.3390\/molecules26040923"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coviro.2016.01.013","article-title":"HSV antivirals\u2014Current and future treatment options","volume":"18","author":"Birkmann","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2019000956","article-title":"How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Einsele","year":"2020","journal-title":"Blood"},{"key":"ref_30","unstructured":"National Center for Biotechnology Information (2022, February 05). PubChem Compound Summary for CID 3415, Foscarnet, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Foscarnet."},{"key":"ref_31","unstructured":"National Center for Biotechnology Information (2022, February 05). PubChem Compound Summary for CID 60613, Cidofovir, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Cidofovir."},{"key":"ref_32","unstructured":"National Center for Biotechnology Information (2022, February 05). PubChem Compound Summary for CID 135398742, Valacyclovir, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Valacyclovir."},{"key":"ref_33","unstructured":"National Center for Biotechnology Information (2022, February 05). PubChem Compound Summary for CID 135398748, Penciclovir, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Penciclovir."},{"key":"ref_34","unstructured":"National Center for Biotechnology Information (2022, February 05). \u201cPubChem Compound Summary for CID 135398740, Ganciclovir\u201d PubChem, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Ganciclovir."},{"key":"ref_35","unstructured":"National Center for Biotechnology Information (2022, February 05). \u201cPubChem Compound Summary for CID 135413535, Valganciclovir\u201d PubChem, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Valganciclovir."},{"key":"ref_36","unstructured":"National Center for Biotechnology Information (2022, February 05). \u201cPubChem Compound Summary for CID 135409256, Filociclovir\u201d PubChem, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Filociclovir."},{"key":"ref_37","unstructured":"National Center for Biotechnology Information (2022, February 05). \u201cPubChem Compound Summary for CID 471161, Maribavir\u201d PubChem, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Maribavir."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/pch\/19.4.201","article-title":"Prevention and management of neonatal herpes simplex virus infections","volume":"19","author":"Allen","year":"2014","journal-title":"Paediatr. Child Health"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1016\/S2214-109X(16)30362-X","article-title":"First estimates of the global and regional incidence of neonatal herpes infection","volume":"5","author":"Looker","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1146\/annurev-virology-092917-043457","article-title":"Antiviral approaches for the treatment of Herpes Simplex Virus infections in newborn infants","volume":"5","author":"Poole","year":"2018","journal-title":"Annu. Rev. Virol."},{"key":"ref_41","first-page":"piab105","article-title":"Neonatal Herpes Simplex Virus infection: Epidemiology and outcomes in the modern era","volume":"11","author":"Melvin","year":"2021","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"ref_42","first-page":"1","article-title":"Acyclovir and hydrocortisone cream for the early treatment of recurrent cold sores","volume":"3","author":"Sailer","year":"2011","journal-title":"Virus Adapt. Treat."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jaad.2010.08.012","article-title":"Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: A randomized, double-blind, placebo-controlled, patient-initiated clinical trial","volume":"64","author":"Hull","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Sadowski, L.A., Upadhyay, R., Greeley, Z.W., and Margulies, B.J. (2021). Current drugs to treat infections with herpes simplex viruses-1 and -2. Viruses, 13.","DOI":"10.3390\/v13071228"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Andrei, G., and Snoeck, R. (2021). Advances and perspectives in the management of Varicella-Zoster Virus infections. Molecules, 26.","DOI":"10.3390\/molecules26041132"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/infdis\/147.3.576","article-title":"Comparative efficacy of antiherpes drugs against various strains of Varicella-Zoster virus","volume":"147","author":"Shigeta","year":"1983","journal-title":"J. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1021\/acs.jmedchem.9b00175","article-title":"Fifty years in search of selective antiviral drugs","volume":"62","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/jac\/dkv285","article-title":"Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes of herpes simplex virus types 1 and 2","volume":"71","author":"Sauerbrei","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_49","unstructured":"Bennett, J.E., Dolin, R., and Blaser, M.J. (2020). Antivirals against Herpesviruses. Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases, Elsevier."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e13526","DOI":"10.1111\/ctr.13526","article-title":"Herpes simplex virus infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Lee","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Perera, M.R., Wills, M.R., and Sinclair, J.H. (2021). HCMV antivirals and strategies to target the latent reservoir. Viruses, 13.","DOI":"10.3390\/v13050817"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.medmal.2018.03.006","article-title":"Maribavir, brincidofovir and letermovir: Efficacy and safety of new antiviral drugs for treating cytomegalovirus infections","volume":"48","author":"Frange","year":"2018","journal-title":"M\u00e9decine et Maladies Infectieuses"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13365-016-0473-0","article-title":"Roseolovirus-associated encephalitis in immunocompetent and immunocompromised individuals","volume":"23","author":"Ablashi","year":"2017","journal-title":"J. Neurovirol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.healun.2006.10.017","article-title":"Human herpesvirus-6 and -7 after lung and heart-lung transplantation","volume":"26","author":"Lehto","year":"2007","journal-title":"J. Heart Lung Transplant."},{"key":"ref_55","first-page":"8996934","article-title":"Difference between acyclovir and ganciclovir in the treatment of children with Epstein\u2013Barr Virus-associated infectious mononucleosis","volume":"2021","author":"Zhang","year":"2021","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Galar, A., Valerio, M., Catal\u00e1n, P., Garc\u00eda-Gonz\u00e1lez, X., Burillo, A., Fern\u00e1ndez-Cruz, A., Zatar\u00e1in, E., Sousa-Casasnovas, I., Anaya, F., and Rodr\u00edguez-Ferrero, M.L. (2021). Valganciclovir-ganciclovir use and systematic therapeutic drug monitoring. An invitation to antivirals stewardship. Antibiotics, 10.","DOI":"10.3390\/antibiotics10010077"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jama.2020.3138","article-title":"Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: A randomized clinical trial","volume":"323","author":"Singh","year":"2020","journal-title":"JAMA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2478\/ahp-2020-0005","article-title":"Prophylaxis vs preemptive therapy in prevention of CMV infection: New insight on prophylactic strategy after allogeneic hematopoietic cell transplantation","volume":"51","year":"2020","journal-title":"Acta Haematol. Pol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","article-title":"Pathogenesis of human cytomegalovirus in the immunocompromised host","volume":"19","author":"Griffiths","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/infdis\/jix263","article-title":"Valganciclovir for the suppression of Epstein-Barr Virus replication","volume":"216","author":"Yager","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/588820","article-title":"Valganciclovir for suppression of human herpesvirus-8 replication: A randomized, double-blind, placebo-controlled, crossover trial","volume":"198","author":"Casper","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.antiviral.2019.05.012","article-title":"UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients","volume":"168","author":"Labrunie","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"104421","DOI":"10.1016\/j.jcv.2020.104421","article-title":"Challenges of aciclovir-resistant HSV infection in allogeneic bone marrow transplant recipients","volume":"128","author":"Mehra","year":"2020","journal-title":"J. Clin. Virol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.antiviral.2014.08.013","article-title":"Resistance of herpes simplex viruses to acyclovir: An update from a ten-year survey in France","volume":"111","author":"Frobert","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.00615-10","article-title":"Resistance of herpes simplex viruses to nucleoside analogues: Mechanisms, prevalence, and management","volume":"55","author":"Piret","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1080\/07391102.2019.1625443","article-title":"Mechanism of resistance to acyclovir in thymidine kinase mutants from Herpes simplex virus type 1: A computational approach","volume":"38","author":"Rabelo","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/rmv.1787","article-title":"Antiviral drug resistance in herpesviruses other than cytomegalovirus","volume":"24","author":"Piret","year":"2014","journal-title":"Rev. Med. Virol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/QCO.0000000000000288","article-title":"Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: Diagnosis and management","volume":"29","author":"Piret","year":"2016","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.clinthera.2018.07.006","article-title":"Antiviral therapies for Herpesviruses: Current agents and new directions","volume":"40","author":"Poole","year":"2018","journal-title":"Clin. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3389\/fmicb.2019.00941","article-title":"Alpha-herpesvirus thymidine kinase genes mediate viral virulence and are potential therapeutic targets","volume":"10","author":"Xie","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1128\/AAC.00669-10","article-title":"Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: Natural polymorphism and mutations associated with resistance to antivirals","volume":"54","author":"Burrel","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1128\/AAC.00977-15","article-title":"Sequence analysis of herpes simplex virus 1 thymidine kinase and DNA polymerase genes from over 300 clinical isolates from 1973 to 2014 finds novel mutations that may be relevant for development of antiviral resistance","volume":"59","author":"Schmidt","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.antiviral.2013.09.008","article-title":"Phenotypic and genotypic characterization of induced acyclovir-resistant clinical isolates of herpes simplex virus type 1","volume":"100","author":"Hussin","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Karamitros, T., Harrison, I., Piorkowska, R., Katzourakis, A., Magiorkinis, G., and Mbisa, J.L. (2016). De novo assembly of Human Herpes Virus Type 1 (HHV-1) genome, mining of non-canonical structures and detection of novel drug-resistance mutations using short- and long-read next generation sequencing technologies. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0157600"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e117928","DOI":"10.5812\/jjm.117928","article-title":"Susceptibility evaluation of clinically isolated HSV-1 strains to acyclovir: A phenotypic and genotypic study","volume":"14","author":"Aliabadi","year":"2021","journal-title":"Jundishapur J. Microbiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.antiviral.2013.09.012","article-title":"Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey","volume":"100","author":"Burrel","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_78","unstructured":"(2022, January 31). Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2020. Available online: https:\/\/www.fhi.no\/globalassets\/dokumenterfiler\/rapporter\/2021\/ravn-rapport-2021.pdf."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-pharmtox-010510-100228","article-title":"A 40-year journey in search of selective antiviral chemotherapy","volume":"51","year":"2011","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Loeffelholz, M., Young, S.A., and Pinksy, B.A. (2016). Clinical Virology Manual, John Wiley & Sons. [5th ed.]. Available online: https:\/\/www.perlego.com\/book\/1343048\/clinical-virology-manual-pdf.","DOI":"10.1128\/9781555819156"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jgar.2019.05.004","article-title":"Herpes simplex virus resistant to acyclovir: A single-centre experience from the Czech Republic","volume":"19","author":"Fajfr","year":"2019","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jcv.2017.08.011","article-title":"Genetic polymorphism of thymidine kinase (TK) and DNA polymerase (pol) of clinical varicella-zoster virus (VZV) isolates collected over three decades","volume":"95","author":"Hoffmann","year":"2017","journal-title":"J. Clin. Virol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jviromet.2016.03.006","article-title":"Complementary assays for monitoring susceptibility of varicella-zoster virus resistance to antivirals","volume":"233","author":"Perrier","year":"2016","journal-title":"J. Virol. Methods"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e13168","DOI":"10.1111\/tid.13168","article-title":"Ganciclovir-resistant post-transplant cytomegalovirus infection due to combined deletion mutation at codons 595-596 of the UL97 gene","volume":"21","author":"Leung","year":"2019","journal-title":"Transpl. Infect. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jcv.2012.01.006","article-title":"Detection of ganciclovir resistance mutations by pyrosequencing in HCMV-infected pediatric patients","volume":"54","author":"Benzi","year":"2012","journal-title":"J. Clin. Virol."},{"key":"ref_86","first-page":"160","article-title":"Ganciclovir treatment failure in adult allogeneic hematopoietic stem cell transplant recipients with cytomegalovirus infection-a single centre experience","volume":"64","author":"Radocha","year":"2015","journal-title":"Epidemiol. Mikrobiol. Imunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"104647","DOI":"10.1016\/j.antiviral.2019.104647","article-title":"Characterization of the dynamics of human cytomegalovirus resistance to antiviral drugs by ultra-deep sequencing","volume":"173","author":"Guermouche","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2217\/fmb-2019-0288","article-title":"Brincidofovir: Understanding its unique profile and potential role against adenovirus and other viral infections","volume":"15","author":"Whited","year":"2020","journal-title":"Future Microbiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"105182","DOI":"10.1016\/j.antiviral.2021.105182","article-title":"Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration\u2019s Evaluation","volume":"195","author":"Harrington","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/FTD.0000000000000353","article-title":"Brincidofovir is not a substrate for the human organic anion transporter 1: A mechanistic explanation for the lack of nephrotoxicity observed in clinical studies","volume":"38","author":"Tippin","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"ref_92","first-page":"9530","article-title":"Distribution and effects of amino acid changes in drug-resistant \u03b1 and \u03b2 herpesviruses DNA polymerase","volume":"44","author":"Topalis","year":"2016","journal-title":"Nucleic. Acids. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/MOT.0000000000000541","article-title":"Drug-resistant cytomegalovirus: Clinical implications of specific mutations","volume":"23","author":"Razonable","year":"2018","journal-title":"Curr. Opin. Organ Transplant."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/CMR.12.2.286","article-title":"Resistance of human cytomegalovirus to antiviral drugs","volume":"12","author":"Erice","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1128\/AAC.00214-16","article-title":"Novel Cytomegalovirus UL54 DNA polymerase gene mutations selected in vitro that confer brincidofovir resistance","volume":"60","author":"Chou","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_96","unstructured":"Garikapati, S., and Nguyen, M. (2022, January 31). Foscarnet, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556108\/."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e0039021","DOI":"10.1128\/AAC.00390-21","article-title":"Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet","volume":"65","author":"Zarrouk","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1128\/JVI.80.3.1440-1450.2006","article-title":"Role of Helix P of the Human Cytomegalovirus DNA Polymerase in Resistance and Hypersusceptibility to the Antiviral Drug Foscarnet","volume":"80","author":"Tchesnokov","year":"2006","journal-title":"J. Virol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2019.01.011","article-title":"Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance","volume":"163","author":"Piret","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e13570","DOI":"10.1111\/tid.13570","article-title":"Letermovir prophylaxis in solid organ transplant\u2014Assessing CMV breakthrough and tacrolimus drug interaction","volume":"23","author":"Winstead","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2040620720937150","DOI":"10.1177\/2040620720937150","article-title":"Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant","volume":"11","author":"Shigle","year":"2020","journal-title":"Ther. Adv. Hematol."},{"key":"ref_102","unstructured":"(2022, January 31). MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04129398?term=letermovir&draw=2&rank=5."},{"key":"ref_103","unstructured":"(2022, January 31). Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03443869?term=letermovir&draw=3&rank=12."},{"key":"ref_104","unstructured":"(2022, January 31). Letermovir for CMV Prevention After Lung Transplantation, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05041426?term=letermovir&draw=2&rank=1."},{"key":"ref_105","unstructured":"(2022, January 31). Letermovir Use in Heart Transplant Recipients, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04904614?term=letermovir&draw=2&rank=4."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2147\/IDR.S180908","article-title":"Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: An evidence-based review","volume":"12","author":"Razonable","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1111\/ajt.16718","article-title":"Letermovir in lung transplant recipients with cytomegalovirus infection: A retrospective observational study","volume":"21","author":"Veit","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/infdis\/jiz642","article-title":"De Novo Genotypic Heterogeneity in the UL56 Region in Cytomegalovirus-Infected Tissues: Implications for Primary Letermovir Resistance","volume":"221","author":"Jo","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e02337-18","DOI":"10.1128\/AAC.02337-18","article-title":"Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis","volume":"63","author":"Turner","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Jung, S., Michel, M., Stamminger, T., and Michel, D. (2019). Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4016-1"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e01325-17","DOI":"10.1128\/AAC.01325-17","article-title":"Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds","volume":"61","author":"Chou","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11899-020-00557-6","article-title":"Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy","volume":"15","author":"Hakki","year":"2020","journal-title":"Curr. Hematol. Malign Rep."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.antiviral.2018.07.013","article-title":"Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus","volume":"157","author":"Chou","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_115","unstructured":"(2022, January 31). Novel Drug Approvals for 2021, Available online: https:\/\/www.fda.gov\/drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products\/novel-drug-approvals-2021."},{"key":"ref_116","first-page":"jiaa462","article-title":"Drug resistance mutations and associated phenotypes detected in clinical trials of maribavir for treatment of cytomegalovirus infection","volume":"29","author":"Chou","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1093\/infdis\/jiab029","article-title":"Phenotype and Genotype Study of Novel C480F Maribavir-Ganciclovir Cross-Resistance Mutation Detected in Hematopoietic Stem Cell and Solid Organ Transplant Recipients","volume":"224","author":"Bravo","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"104616","DOI":"10.1016\/j.antiviral.2019.104616","article-title":"Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","volume":"172","author":"Chou","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"104711","DOI":"10.1016\/j.antiviral.2020.104711","article-title":"Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance","volume":"176","author":"Chou","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study","volume":"68","author":"Papanicolaou","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"11499","DOI":"10.1128\/JVI.77.21.11499-11506.2003","article-title":"Resistance of Human Cytomegalovirus to the Benzimidazole l -Ribonucleoside Maribavir Maps to UL27","volume":"77","author":"Komazin","year":"2003","journal-title":"J. Virol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Bogner, E., Egorova, A., and Makarov, V. (2021). Small Molecules\u2014Prospective Novel HCMV Inhibitors. Viruses, 13.","DOI":"10.3390\/v13030474"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/clpt.2010.178","article-title":"Update on New Antivirals Under Development for the Treatment of Double-Stranded DNA Virus Infections","volume":"88","author":"Dropulic","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1517\/14728222.2013.827663","article-title":"The DNA helicase-primase complex as a target for herpes viral infection","volume":"17","author":"Weller","year":"2013","journal-title":"Expert Opin. Ther. Targets."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/jac\/dkq198","article-title":"ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2","volume":"65","author":"Chono","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_126","unstructured":"National Center for Biotechnology Information (2022, February 03). PubChem Compound Summary for CID 11397521, Amenamevir, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Amenamevir."},{"key":"ref_127","unstructured":"National Center for Biotechnology Information (2022, February 03). PubChem Compound Summary for CID 491941, Pritelivir, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Pritelivir."},{"key":"ref_128","unstructured":"National Center for Biotechnology Information (2022, February 03). PubChem Compound Summary for CID 135398513, Acyclovir, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Acyclovir."},{"key":"ref_129","unstructured":"National Center for Biotechnology Information (2022, February 03). PubChem Compound Summary for CID 3324, Famciclovir, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Famciclovir."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"eabf8668","DOI":"10.1126\/scitranslmed.abf8668","article-title":"A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections","volume":"13","author":"Gege","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1056\/NEJMoa1301150","article-title":"Helicase\u2013Primase Inhibitor Pritelivir for HSV-2 Infection","volume":"370","author":"Wald","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/jama.2016.18189","article-title":"Effect of Pritelivir Compared with Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences","volume":"316","author":"Wald","year":"2016","journal-title":"JAMA"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1177\/09564624211006568","article-title":"Use of pritelivir in refractory aciclovir-resistant herpes simplex virus type 2","volume":"32","author":"Cannon","year":"2021","journal-title":"Int. J. STD AIDS"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"324ra15","DOI":"10.1126\/scitranslmed.aad6654","article-title":"Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes","volume":"8","author":"Schiffer","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_135","unstructured":"(2022, January 31). Trial on Efficacy and Safety of Pritelivirtablets for Treatment of Acyclovir-Resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (PRIOH-1), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03073967?term=pritelivir&draw=2&rank=2."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/infdis\/jiw129","article-title":"No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy","volume":"214","author":"Edlefsen","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e00494-21","DOI":"10.1128\/AAC.00494-21","article-title":"Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus","volume":"65","author":"Sato","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/095632020801900101","article-title":"Herpes Simplex Virus Helicase\u2014Primase Inhibitors: Recent Findings from the Study of Drug Resistance Mutations","volume":"19","author":"Biswas","year":"2008","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nm0402-386","article-title":"Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease","volume":"8","author":"Crute","year":"2002","journal-title":"Nat. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bcp.2018.10.024","article-title":"Antiviral efficacy of the helicase-primase inhibitor amenamevir in murine models of severe herpesvirus infection","volume":"158","author":"Katsumata","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/jis019","article-title":"ASP2151 for the Treatment of Genital Herpes: A Randomized, Double-Blind, Placebo- and Valacyclovir-Controlled, Dose-Finding Study","volume":"205","author":"Tyring","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bcp.2012.05.020","article-title":"Characterization of virus strains resistant to the herpes virus helicase\u2013primase inhibitor ASP2151 (Amenamevir)","volume":"84","author":"Chono","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/1346-8138.15393","article-title":"Pharmaceuticals and Medical Device Agency approval summary: Amenamevir for the treatment of herpes zoster","volume":"47","author":"Shoji","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/jac\/dkn057","article-title":"A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase\u2013primase inhibitors in their mode of interaction with the antiviral target","volume":"61","author":"Biswas","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"105189","DOI":"10.1016\/j.antiviral.2021.105189","article-title":"High conservation of varicella-zoster virus helicase-primase complex, the target of the new antiviral drug amenamevir","volume":"195","author":"Pacreau","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/15257770701257210","article-title":"Fluoroanalogues of Anti-Cytomegalovirus Agent Cyclopropavir: Synthesis and Antiviral Activity of (E)- and (Z)-9-{[2,2-Bis(Hydroxymethyl)-3-Fluorocyclopropylidene]Methyl}-Adenines and Guanines","volume":"26","author":"Zhou","year":"2007","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1128\/AAC.00449-16","article-title":"Potency and Stereoselectivity of Cyclopropavir Triphosphate Action on Human Cytomegalovirus DNA Polymerase","volume":"60","author":"Chen","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"104710","DOI":"10.1016\/j.antiviral.2020.104710","article-title":"The discovery and development of filociclovir for the prevention and treatment of human cytomegalovirus-related disease","volume":"176","author":"Hussein","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Chen, S.J., Wang, S.C., and Chen, Y.C. (2019). Antiviral Agents as Therapeutic Strategies Against Cytomegalovirus Infections. Viruses, 12.","DOI":"10.3390\/v12010021"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e00717-19","DOI":"10.1128\/AAC.00717-19","article-title":"Phase Ib Trial to Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of Filociclovir (MBX-400, Cyclopropavir) in Healthy Volunteers","volume":"63","author":"Rouphael","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Toscani, A., Denaro, R., Pacheco, S.F.C., Biolatti, M., Anselmi, S., Dell\u2019Oste, V., and Castagnolo, D. (2021). Synthesis and Biological Evaluation of Amidinourea Derivatives against Herpes Simplex Viruses. Molecules, 26.","DOI":"10.3390\/molecules26164927"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12985-021-01581-5","article-title":"Inhibition of herpes simplex virus-1 infection by MBZM-N-IBT: In silico and in vitro studies","volume":"18","author":"Kumar","year":"2021","journal-title":"Virol. J."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"105057","DOI":"10.1016\/j.antiviral.2021.105057","article-title":"Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication","volume":"189","author":"Luganini","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Przybylska, D., Kucharska, A.Z., Cybulska, I., Soza\u0144ski, T., Pi\u00f3recki, N., and Fecka, I. (2020). Cornus mas L. Stones: A Valuable By-Product as an Ellagitannin Source with High Antioxidant Potential. Molecules, 25.","DOI":"10.3390\/molecules25204646"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1128\/JVI.01492-10","article-title":"Hydrolyzable Tannins (Chebulagic Acid and Punicalagin) Target Viral Glycoprotein-Glycosaminoglycan Interactions to Inhibit Herpes Simplex Virus 1 Entry and Cell-to-Cell Spread","volume":"85","author":"Lin","year":"2011","journal-title":"J. Virol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.antiviral.2014.07.017","article-title":"Ellagitannins as synergists of ACV on the replication of ACV-resistant strains of HSV 1 and 2","volume":"110","author":"Jacquet","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_157","unstructured":"Centers for Disease Control and Prevention (CDC) (2013). Updated recommendations for use of VariZIG\u2014United States, 2013. Morb. Mortal. Wkly. Rep., 62, 574\u2013576."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"469","DOI":"10.21775\/cimb.041.469","article-title":"Alphaherpesvirus Vaccines","volume":"41","author":"Aschner","year":"2021","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/ITT.S176383","article-title":"Varicella zoster virus vaccines: An update","volume":"8","author":"Gabutti","year":"2019","journal-title":"ImmunoTargets Ther."},{"key":"ref_160","first-page":"5","article-title":"Shingrix for herpes zoster: A review","volume":"24","author":"Shah","year":"2019","journal-title":"Skin. Ther. Lett."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Gerna, G., and Lilleri, D. (2020). Human Cytomegalovirus Congenital (cCMV) Infection Following Primary and Nonprimary Maternal Infection: Perspectives of Prevention through Vaccine Development. Vaccines, 8.","DOI":"10.3390\/vaccines8020194"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1093\/infdis\/jiz428","article-title":"Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease","volume":"221","author":"Nelson","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Manandhar, T., H\u00f2, G.-G.T., Pump, W.C., Blasczyk, R., and Bade-Doeding, C. (2019). Battle between Host Immune Cellular Responses and HCMV Immune Evasion. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20153626"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"4670","DOI":"10.1038\/s41467-019-12641-4","article-title":"HCMV-encoded US7 and US8 act as antagonists of innate immunity by distinctively targeting TLR-signaling pathways","volume":"10","author":"Park","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1080\/21645515.2017.1391433","article-title":"Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy","volume":"14","author":"Xia","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1093\/infdis\/jiz447","article-title":"The status of vaccine development against the human cytomegalovirus","volume":"221","author":"Plotkin","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Scarpini, S., Morigi, F., Betti, L., Dondi, A., Biagi, C., and Lanari, M. (2021). Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice. Vaccines, 9.","DOI":"10.3390\/vaccines9060551"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/infdis\/jiz141","article-title":"Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects","volume":"220","author":"Adler","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_169","unstructured":"(2021, November 29). V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03486834."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial","volume":"34","author":"Bernstein","year":"2015","journal-title":"Vaccine"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ebiom.2019.11.005","article-title":"Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation","volume":"50","author":"Baraniak","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_172","first-page":"771","article-title":"Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax","volume":"25","author":"Longmate","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_173","unstructured":"(2021, November 29). Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients with Hematologic Malignancies Undergoing Donor Stem Cell Transplant, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02396134."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1128\/CVI.00662-13","article-title":"Enveloped Virus-Like Particle Expression of Human Cytomegalovirus Glycoprotein B Antigen Induces Antibodies with Potent and Broad Neutralizing Activity","volume":"21","author":"Kirchmeier","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_175","unstructured":"(2021, November 29). Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02826798."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e00300-16","DOI":"10.1128\/CVI.00300-16","article-title":"Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B\/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector","volume":"24","author":"Schleiss","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_177","unstructured":"(2021, November 29). A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03629080."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"306","DOI":"10.7326\/M19-2511","article-title":"Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients","volume":"172","author":"Aldoss","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"100787","DOI":"10.1016\/j.eclinm.2021.100787","article-title":"A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients","volume":"33","author":"Ljungman","year":"2021","journal-title":"eClinicalMedicine"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12185-016-2110-3","article-title":"Safety of ASP0113, a cytomegalovirus DNA vaccine, in recipients undergoing allogeneic hematopoietic cell transplantation: An open-label phase 2 trial","volume":"105","author":"Mori","year":"2016","journal-title":"Int. J. Hematol."},{"key":"ref_181","unstructured":"(2021, November 29). Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03382405."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.vaccine.2018.01.029","article-title":"Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity","volume":"36","author":"John","year":"2018","journal-title":"Vaccine"},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Ayoub, H.H., Chemaitelly, H., and Abu-Raddad, L.J. (2020). Epidemiological impact of novel preventive and therapeutic HSV-2 vaccination in the United States: Mathematical modeling analyses. Vaccines, 8.","DOI":"10.3390\/vaccines8030366"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.vaccine.2008.11.074","article-title":"Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa","volume":"27","author":"Freeman","year":"2009","journal-title":"Vaccine"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1103151","article-title":"Herpevac trial for women. Efficacy results of a trial of a herpes simplex vaccine","volume":"366","author":"Belshe","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"eaax2454","DOI":"10.1126\/sciimmunol.aax2454","article-title":"HVEM signaling promotes protective antibody-dependent cellular cytotoxicity (ADCC) vaccine responses to herpes simplex viruses","volume":"5","author":"Aschner","year":"2020","journal-title":"Sci. Immunol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"10373","DOI":"10.3389\/fimmu.2019.00373","article-title":"Mechanisms of immune control of mucosal HSV infection: A guide to rational vaccine design","volume":"10","author":"Truong","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3389\/fcimb.2019.00127","article-title":"Herpes simplex virus evasion of early host antiviral responses","volume":"9","author":"Tognarelli","year":"2019","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1128\/JVI.01130-14","article-title":"Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes","volume":"88","author":"Awasthi","year":"2014","journal-title":"J. Virol."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Egan, K.P., Hook, L.M., Naughton, A., Pardi, N., Awasthi, S., Cohen, G.H., Weissman, D., and Friedman, H.M. (2020). An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008795"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.trsl.2020.03.004","article-title":"Vaccines to prevent genital herpes","volume":"220","author":"Egan","year":"2020","journal-title":"Transl. Res."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"9825","DOI":"10.1128\/JVI.01387-15","article-title":"Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D\/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model","volume":"89","author":"Boukhvalova","year":"2015","journal-title":"J. Virol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1016\/j.vaccine.2019.05.009","article-title":"Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease","volume":"37","author":"Bernstein","year":"2019","journal-title":"Vaccine"},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Ike, A.C., Onu, C.J., Ononugbo, C.M., Reward, E.E., and Muo, S.O. (2020). Immune Response to Herpes Simplex Virus Infection and Vaccine Development. Vaccines, 8.","DOI":"10.3390\/vaccines8020302"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Chandra, J., Woo, Y., Dutton, J.L., Xu, Y., Li, B., Kinrade, S., Druce, J., Finlayson, N., Griffin, P., and Laing, K.J. (2019). Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I\/IIa trial. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0226320"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.vaccine.2005.08.088","article-title":"A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects","volume":"24","author":"Warren","year":"2006","journal-title":"Vaccine"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/infdis\/jiz225","article-title":"A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults with or Without HSV Infection","volume":"220","author":"Dropulic","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Halford, W.P., Geltz, J., Messer, R.J., and Hasenkrug, K.J. (2015). Antibodies Are Required for Complete Vaccine-Induced Protection against Herpes Simplex Virus 2. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0145228"},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Stanfield, B.A., Kousoulas, K.G., Fernandez, A., and Gershburg, E. (2021). Rational Design of Live-Attenuated Vaccines against Herpes Simplex Viruses. Viruses, 13.","DOI":"10.3390\/v13081637"},{"key":"ref_200","unstructured":"(2021, November 29). Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults with Recurrent Genital Herpes Caused by HSV 2 (HSV15), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04222985."},{"key":"ref_201","unstructured":"(2021, November 29). HSV529 Vaccine in HSV-2 Seropositive Adults, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02571166."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Joyce, J., Patel, A., Murphy, B., Carr, D., Gershburg, E., and Bertke, A. (2021). Assessment of Two Novel Live-Attenuated Vaccine Candidates for Herpes Simplex Virus 2 (HSV-2) in Guinea Pigs. Vaccines, 9.","DOI":"10.3390\/vaccines9030258"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/infdis\/jiy415","article-title":"Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital Herpes Simplex Virus-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-Controlled Trial","volume":"218","author":"Fife","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_204","unstructured":"(2021, November 29). Maintenance Dose Study of GEN-003 in Subjects with Genital Herpes Infection, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03146403."},{"key":"ref_205","unstructured":"(2021, November 29). Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants with Recurrent Genital Herpes, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01687595."},{"key":"ref_206","unstructured":"(2021, November 29). Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine (HSV-2), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02837575."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/7\/3431\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:40:57Z","timestamp":1760136057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/7\/3431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":206,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["ijms23073431"],"URL":"https:\/\/doi.org\/10.3390\/ijms23073431","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,22]]}}}